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Abstract: Pentoxifylline modifi es central and peripheral vagal mechanism in acute and chronic 
pain models.
The infl ammatory process gives the way to hyperalgesia that is documented by the animal 
experimental studies. Pentoxifylline (PTX) has strong antyinfl amatory effects, decreases TNF-alpha 
and other proinfl ammatory cytokines production. Therefore, the aim of present investigation was 
to evaluate the effectiveness of PTX in nociception processes, especially in aspects of vagal activity, 
in experimental pain models: visceral pain (VP), neuropathy (CCI) and neurogenic infl ammation 
(NI). In VP and CCI models we observed signifi cant increase in the pain threshold after blocking 
proinfl ammatory cytokines whereas in NI there was no such effect. In our studies we also observed 
the increase of vagal afferents activity in VP and CCI, on the contrary to NI model. In summary, 
our study demonstrates that preemptive inhibition of proinfl ammatory cytokine synthesis by 
treatment with PTX is useful in antagonizing hyperalgesia in infl ammatory pain. Pentoxifylline 
reduces central and peripheral sensitization processes depend on the vagal component in both 
acute and chronic pain models but in a different manner and mechanisms. Our results establish 
the participation of infl ammatory and vagal component in nociception. The modulation of the 
vagal system offers the new possibilities of the pain treatment in patients resistant to the classical 
analgesic therapy.
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INTRODUCTION
There is increasing evidence showing that sensitization processes are not only 
controlled by spinal afferent fi bers but it is also related to vagal afferent fi bers 
[1–4]. Hypersensitivity in response to mechanical and chemical stimuli results 
from the sensitization of the primary afferent neurons (peripheral hyperalgesia) 
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and the nociceptive pathways in the central nervous system (CNS) (central 
hyperalgesia) [5, 6]. The vagus nerve, the largest sensory nerve in the body, 
and its involvement in infl ammatory response, can be a target for anti-pain 
therapy lately, due to growing evidence that indicates its contribution in 
nociception.
Vagotomy studies demonstrate that vagal afferent integrity is essential to 
the effi cacy of different analgesic treatments like morphine [7]. Furthermore, 
subdiaphragmatic vagotomy decreases the threshold for paw withdrawal in 
rats [8], increases sensitivity to noxious lesions [9] and enhances hyperalgesia 
induced by the potent infl ammatory mediator bradykinin [10, 11]. However, 
vagotomy also prevents the establishment of kainic acid-induced hyperalgesia 
in mice [12] and reduces nociception in the formalin test in male rats [13]. 
On the other hand an anti-nociceptive action of VNS is reported in numerous 
studies which describe for instance inhibition of the nociceptive refl ex [14, 15] 
or latency increase of the tail-fl ick response to heat in rats [16]. However, 
pronociceptive effects have also been reported in the tail-fl ick test in rats [17]. 
These discrepancies can be explained by differences in stimulation parameters : 
low intensity stimulations of vagal afferents facilitate, while high intensity 
stimulations inhibit nociception [7]. According to Ren et al., the analgesic 
effect of VNS seems to depend on a critical stimulation intensity that activates 
C-fi bers [18]. 
Pentoxifylline (PTX), a nonspecifi c phosphodiesterase inhibitor, has several 
actions that improve blood rheology and tissue perfusion and it is used 
clinically as a treatment for intermittent claudication [19]. Several laboratory 
investigations, however, employ the drug for its anticytokine effects. Previously 
several reports demonstrate that PTX administration virtually eliminates 
the up-regulation of cytokines in various pain models [20–26]. Its infl uence 
on infl ammatory component of sensitization processes is well known, but 
on the vagal dependent mechanisms, remain unclear [27]. Thus the aim of 
present investigation was to evaluate the effectiveness of PTX in peripheral 
and central sensitization processes, especially in aspects of vagal activity, in 
experimental pain models; visceral pain (VP), neuropathy (CCI) and neurogenic 
infl ammation (NI).
MATERIALS AND METHODS
Experimental procedures were performed on 130 Wistar rats in Pathophysiology 
Department of the Collegium Medicum, Jagiellonian University in Kraków. 
All the procedures were conducted with the approval of the I Local Ethical 
Committee for the Animal Studies in Kraków. 
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In this study we analyzed modifi cation of vagus nerve activity (electrical 
activity) and c-Fos expression in vagal nodose ganglion (NG) after PTX 
administration. To estimate the intensity of pain symptoms manifestations 
we provided the behavioral tests adequate to the pain model: abdominal 
constriction test (WT) in VP, von Frey test to assess mechanical allodynia and 
Hargreaves test to assess thermal hyperalgesia in CCI and NI. 
Pa in  mode l s
Visceral Pain (VP). There was used accepted animal model of the viscero-somatic 
pain [28, 29]. By injecting i.p. 0,5% acetic acid (10 ml/kg) there was induced 
chemical peritonitis.
Neuropathic pain (CCI). In the experiment there was used Bennet and 
Xie model of chronic constriction injury (CCI) [30]. The behavioral tests were 
performed before the surgical procedure (day 0) and then on 14th day after the 
procedure. In our experiments the control group was the one, in which there 
was conducted the surgical procedure but without injuring the nerve itself 
(sham), additionally the healthy leg (contralateral, contra) — in every subgroup 
served as a control. These was evaluated and compared to the group with 
“pure” neuropathic pain (CCI) as the behavioral response of the injured leg 
(ipsilateral — ipsi). 
Neurogenic Infl ammation (NI). Approved Gilchrist’s model was used for 
induction of NI. Mechanical and thermal stimuli were administered 3 mm 
proximally to capsaicin injection place (highest pain response zone) [31].
Behav i o ra l  t e s t s
Behavioral response in acute visceral pain — Writhing Test (WT). Intraperitoneal 
administration of acetic acid causes peritonitis and behavioral manifestation of 
nociception. The intensity of nociception was measured by counting of the rat’s 
abdominal and hind limb muscles contractions (WT) in a period of 30 minutes 
after acetic acid administration. 
Von Frey’s test — test of mechanical allodynia. The von Frey’s test is used 
to evaluation of the behavioral response to mechanical nociceptive stimuli 
[32, 33]. The experimental procedures were conducted by using automatic von 
Frey’s fi lament (Dynamic Plantar Aesthesiometer — Ugo Basile, Italy). 
Hargreaves’s Test — test of thermal hyperalgesia. The Hargreaves’ test is 
used to evaluation of the sensitivity to the thermal nociceptive stimuli [34]. To 
the tests there was used Plantar Test apparatus (Ugo Basile, Italy). 
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E lec t r i ca l  a c t i v i t y  o f  the  l e f t  vagus  ne rve
Under general anesthesia the left vagus nerve was exposed on the neck and 
recorded because it contains more afferent fi bers [35]. Furthermore in the 
trials conducted in the Pathophysiology Department there weren’t observed any 
differences between the left and right vagus nerve activity [36]. The nerve trunk 
was dissected transversely. On the distal part cuff electrode was placed. The 
signal was amplifi ed and converted by using the standard set (PowerLab/8SP 
ADInstruments Australia and AC/DC Differential Amplifi er A-M Systems USA). 
The records were archived and then worked up by using packet of software 
Chart 5 Pro ver. 5.4.2 extended with Spike Histogram v.1.2 (ADInstruments, 
Australia), compatible with Windows XP system. All the results were given as 
the mean ± standard deviation and statistically worked out. For the signifi cant 
accepted p values were p < 0,05. 
c -Fos  express i on  in  nodose  gang l i on  (NG )
After Vetbutal overdosing inferior vagal ganglions (NG, nodose ganglions) were 
bilaterally prepared and sampled to histochemical evaluations. The prepara-
tions were fi xed and then frozen. Frozen preparation was sliced by using cryo-
stat and subsequently submitted to the immunohistochemical staining. The 
specimens were incubated with rabbit c-Fos antibody (K-25; Sc-253) (Santa 
Cruz Biotechnology). After 3 times repeated PBS washing the specimens were 
incubated with second degree biotinylated goat anti-rabbit antibody (Jack-
son ImmunoResearch, West Grave, PA). Afterwards the specimens were in-
cubated with streptavidin — Cy3 complex (Jackson ImmunoResearch, West 
Grave, PA). Then the specimens were embedded in fl uorescent specimen’s me-
dium  (DAKOCytomation, Denmark). Negative controls were conducted without 
the fi rst antibody. The specimens were analyzed under the Zeiss Axsioscop 
fl uorescent microscope. 
PTX  p re - empt i v e  ana l gesy
To the rats in the proper groups there was pre — emptively administered i.p. 
PTX in a dosage 10 mg/kg b.m. In the VP and NI groups PTX was given 15 
minutes before conducting the behavioral tests. In the CCI group PTXwas 
administered every 12 hours during the experimental duration time — fi rst 
dosage the animals received 6 hours prior to the surgery. The aim was to limit 
the infl ammatory response in the evaluated groups. 
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Sta t i s t i ca l  ana l ys i s
The calculations were performed with using STATISTICA 8.0 for Windows 
packet (StatSoft Inc., Tulusa, Oklahoma, USA). The results were given in the 
tabular and graphic form with using Microsoft Offi ce Excel 2007 software. 
Conformity of the quantitative variables distribution with the normal distribution 
was evaluated with using Shapiro–Wilk test. The results obtained from the 
analysis were given as the arithmetical mean ± standard deviation. As the 
statistically signifi cant results there were accepted those with the difference on 
the level p < 0,05. Graphs were made as deviation from control group (“pure” 
pain model). 
RESULTS
V i sce ra l  pa in  (VP). In model of VP we monitored the direct participation 
of the vagus nerve in mechanisms of visceral nociception which dominated 
over classic spinal pain pathways. PTX administration before experiment in 
visceral nociception decreased the pain response. Intra-peritoneal acetic acid 
administration increased both the vagal afferent discharges frequency and 
c-Fos expression in NG whereas pre-PTX administration suppressed this effect 
(Fig. 1, Tab. 1). 
Fig. 1. Pain response (WR) and vagal activity after PTX administration in visceral pain.
Results are shown as deviation from VP group (0%) (** — p < 0.01)
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T a b l e  1
Pain response (WR) and vagal activity after PTX administration in visceral pain
WR — number of writhes/30 min, Vagal Afferent Activity — frequency of impulses (Hz),
c-Fos Expression — number of c-Fos positive cells/slide of NG
WR Vagal Afferent Activity c-Fos Expression
control 42.3 ± 2.1 1.78 ± 0.34 18 ± 1.5
VP+PTX 22.2 ± 1.9 0.56 ± 0.17 13.2 ± 1.3
N e u r o p a t h i c  p a i n  (CCI). The vagus nerve plays an important role in 
sensitization trough the development of chronic pain (CCI). In model of chronic 
pain (CCI) the vagus nerve is participating indirectly in both of peripheral and 
central sensitisation. The pain threshold signifi cantly increased after PTX. It 
allows to assume, that on the development of mechanical allodynia and of 
thermal hyperalgesia contribution of the vagus nerve is essential. Vagal afferents 
activity and c-fos expression in NG neurons in the CCI group increased. In the 
PTX group the vagus nerve activity and the c-Fos expression were lower in 
comparison to CCI (Fig. 2, Tab. 2), it demonstrate central modifi cation of vagal 
components. 
Fig. 2. Behavioral Tests and vagal activity after PTX administration in CCI model.
Results are shown as deviation from “pure” CCI group (0) (* — < 0.05, ** — p < 0.01)
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T a b l e  2
Behavioral Tests and vagal activity after PTX administration in CCI model
Von Frey’s Test — fi lament pressure (g), Hargreave’s Test — time of paw withdrawal (s), 
Vagal Afferent Activity — frequency of impulses (Hz), c-Fos Expression — number of c-Fos 
positive cells/slide of NG
Von Frey’s Test Hargreave’s Test Vagal Afferent Activity c-Fos Expression
control (CCI) 15.4 ± 1.4 6.5 ± 0.9 0.31 ± 0.05 20.9 ± 1.4
CCI+PTX 18.7 ± 1.7 7.1 ± 0.8 0.25 ± 0.03 15.8 ± 1.2
N e u r o g e n i c  i n f l a m m a t i o n  (NI). We observed attenuation of vagal 
afferent activity in the left vagus nerve and absence of c-Fos expression in NG 
in the NI group. PTX didn’t infl uence the activity of the vagus nerve (Fig. 3, 
Tab. 3). These results support hypothesis of blockade of the central vagal 
centers in order to facilitate the nociceptive information transmitted by spinal 
pathways. 
Fig. 3. Behavioral Tests and vagal activity after PTX administration in NI model.
Results are shown as deviation from “pure” NI group (0) (* — p < 0.05)
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Table  3
Behavioral Tests and vagal activity after PTX administration in NI model
Von Frey’s Test — fi lament pressure (g), Hargreave’s Test — time of paw withdrawal (s), 
Vagal Afferent Activity — frequency of impulses (Hz), c-Fos Expression — number of c-Fos 
positive cells/slide of NG
Von Frey’s Test Hargreave’s Test Vagal Afferents Activity c-Fos Expression
control 18.2 ± 2 7.6 ± 1 0.06 ± 0.01 5.1 ± 1
NI+PTX 19.06 ± 1.25 8.4 ± 1.1 0.057 ± 0.01 5.4 ± 1.7
DISCUSSION
PTX has strong antyinflamatory effects, decreases TNF-alpha and other 
proinfl ammatory cytokines (Il-1, Il-6, Il-8) production [37, 38]. In VP and CCI 
models we observed signifi cant increase in the pain threshold after blocking 
proinfl ammatory cytokines (PTX) whereas in NI there was no such effect [39]. 
Development of the local infl ammatory process activates the cells of the immune 
system, which release numerous infl ammatory mediators, such as cytokines, 
leukotrienes, prostaglandins, proteases, kinins, histamine. These mediators 
activate the sensory neurons or/and change their sensitivity [40–43]. The 
infl ammatory process gives the way to hyperalgesia that is documented by the 
animal experimental studies [44, 45]. In our studies we observed the increased 
electrical activity of the left vagus nerve in VP and CCI, on the contrary to 
NI model. Vagal afferent fi bers, due to the expression of the proinfl ammatory 
cytokines receptors, have a special place in the communication between 
immune system and CNS [46, 47]. Most of the authors describes the vagus 
nerve as responsible mostly for leading the physiological stimuli [48], however 
there are several data confi rming its role in pathophysiology of the nociceptive 
processes [4, 49, 50]. Pain stimulation after tissue damage and infl ammation 
modifi es nervous system response in important processes of peripheral and 
central sensitization. Vagus nerve plays a crucial role in the development of the 
autonomic anti–infl ammatory refl exes [51, 52]. This confi rms the Watkins et al. 
data, stating that post–infl ammatory hyperalgesia depends on the vagal afferent 
pathways integrity [53]. PTX was more effective in reduce of vagal afferents 
discharge in VP than in CCI model and it wasn’t effective in NI model. We 
also observed that PTX administration signifi cantly reduced c-Fos expression 
in nodose ganglon in VP, and even stronger in CCI model. In CCI model c-Fos 
expression in Dorsal Root Ganglia (DRG), spinal cord [54, 55], and in NTS 
[56, 57] increased. Complete dissection of the sciatic nerve also increased c-Fos 
expression in spinal cord [58] that with reference to our studies may prove 
the central sensitization, which may be mediated via vagal pathway. However 
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in antigen-induced arthritis (AIA) the c-Fos expression decreased in spinal 
cord [59]. According to Zhao et al. pain response to mechanical stimuli and 
to increased temperature in neuropathy doesn’t depend on the sympathetic 
nervous system [60]. There exists no marked evidence concerning the vagal 
participation in the acute peripheral pain models. Data obtained in our studies 
show that vagal afferent endings plays the crucial role in the chemical peritonitis 
model (VP). We observed increased vagal afferents activity and c-Fos expression 
in NG. Our fi nding is consistent with the others studies, reporting increase of 
gastric vagal afferents discharge and c-Fos expression in NTS induced by the 
different types of noxious stimuli [61, 62]. Holzer et al. show that exposure of 
the rat gastric mucosa to noxious stimuli is signaled to the brainstem, but 
not spinal cord. This observation is complemented by the fi nding that the 
visceromotor response to gastric acid challenge is suppressed by vagotomy, 
but not splanchnectomy [61, 63]. In other studies after intraperitoneal injection 
of IL-1β and LPS increased c-Fos expression in NTS and NG also confi rms 
our results [64, 65]. The involvement of the central modulation of spinal 
antinociceptive systems with the vagus nerve was observed in the rectum 
stretching model [66]. The participation of the vagal component in the chronic 
pain doesn’t limit itself only to the central nociception modulation. In the CCI 
model we observed complex, coming probably from the existence of “neuronal 
plasticity”, vagal participation in the modulation, both peripheral and central 
sensitization [5, 6]. These observations suggest that the vagus nerve may 
infl uence nociceptive information on many levels of its transmission, being in 
a close correlation with the immune and endocrine system especially at CNS 
level. In NI model we observed also the slight infl uence of the pre-emptively 
administered PTX on thermal hyperalgesia that could be a result of the acute 
character of the study and a lack of proper time for complete development of 
central sensitization [67]. Similar conclusions are coming from Obara et al. 
studies, where there was observed in CCI bigger infl uence of the infl ammatory 
component on the pain threshold increase than in NI [68]. This may confi rm 
the crucial role of the classic, nociceptive pathway in this model. Our results 
establish the participation of infl ammatory and vagal component in nociception 
what can constitute the base for using this tracks in both acute and chronic pain 
complexes treatment. Anti-infl ammatory substances (like PTX), by decreasing 
spinal and vagal activity, may modify peripheral and central sensitization. The 
vagus nerve is directly involved in the visceral nociceptive mechanisms, showing 
the predominance over the classical, spinal nociceptive pathways. Its activity 
depends on the infl ammatory component — so, it shows also antinociceptive 
action, dependent on the efferent pathways of the infl ammatory refl ex. In the 
neuropathic pain model vagus nerve is indirectly involved, playing its role in 
the peripheral and central sensitization mechanisms. The vagus nerve may 
modulate the higher CNS centers that are taking part in the nociception (classical 
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antinociceptive systems, endocrine system (HPA axis)). There is observed the 
central modulation of the vagal system through the spinal component that is 
playing the crucial role in the peripheral nociception. Pre-emptive blockage of 
the proinfl ammatory cytokines diminishes the development of the neuropathic 
signs. Suppression of pro-infl ammatory mediators synthesis in NI attenuates 
pain response not signifi cantly what can result from the used type of acute 
pain model and insuffi cient time needed for the full sensitization development.
In summary, our study demonstrates that preemptive inhibition of pro-
infl ammatory cytokine synthesis by treatment with PTX is useful in antago-
nizing hyperalgesia in infl ammatory pain. Pentoxifylline reduces central and 
peri pheral sensitization processes depend on the vagal component in both 
acute and chronic pain models but in a different manner and mechanisms. 
Our results establish the participation of infl ammatory and vagal component in 
nociception. The modulation of the vagal system offers the new possibilities of 
the pain treatment in patients resistant to the classical analgesic therapy.
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